Incannex Healthcare Limited
Incannex Healthcare Limited (IXHL) Financial Performance & Income Statement Overview
View comprehensive annual and quarterly summaries for Incannex Healthcare Limited (IXHL), featuring income statements, balance sheets, and cash flow data.
Incannex Healthcare Limited (IXHL) Income Statement & Financial Overview
Review Incannex Healthcare Limited IXHL income statement with detailed quarterly and annual figures.
Metric | Q2 2025 | Q4 2024 | Q2 2024 | Q4 2023 |
---|---|---|---|---|
Revenue | $12000.00 | $12000.00 | $0.00 | $0.00 |
Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Gross Profit | $12000.00 | $12000.00 | $0.00 | $0.00 |
Gross Profit Ratio | $1.00 | $1.00 | $0.00 | $0.00 |
R&D Expenses | $1.41M | $4.36M | $2.64M | $1.71M |
SG&A Expenses | $3.60M | $5.40M | $5.34M | $2.48M |
Operating Expenses | $5.02M | $9.76M | $7.98M | $4.19M |
Total Costs & Expenses | $5.02M | $9.76M | $7.98M | $4.19M |
Interest Income | $28000.00 | $40000.00 | $20000.00 | $0.00 |
Interest Expense | $171000.00 | $0.00 | $0.00 | $0.00 |
Depreciation & Amortization | $719000.00 | $62000.00 | $12000.00 | $1000.00 |
EBITDA | -$5.004M | -$6.40M | -$5.24M | -$4.19M |
EBITDA Ratio | -$417.00 | -$533.17 | $0.00 | |
Operating Income | -$5.004M | -$9.74M | -$7.98M | -$4.19M |
Operating Income Ratio | -$417.00 | -$812.00 | $0.00 | |
Other Income/Expenses (Net) | -$890000.00 | $3.31M | $2.74M | $20000.00 |
Income Before Tax | -$5.89M | -$6.43M | -$5.24M | -$4.17M |
Income Before Tax Ratio | -$491.17 | -$535.92 | $0.00 | |
Income Tax Expense | $0.00 | $30000.00 | $0.00 | $0.00 |
Net Income | -$5.89M | -$6.46M | -$5.24M | -$4.17M |
Net Income Ratio | -$491.17 | -$538.42 | $0.00 | |
EPS | -$0.33 | -$0.38 | -$0.33 | -$0.26 |
Diluted EPS | -$0.33 | -$0.38 | -$0.33 | -$0.26 |
Weighted Avg Shares Outstanding | $17.62M | $17.04M | $15.87M | $15.87M |
Weighted Avg Shares Outstanding (Diluted) | $17.62M | $17.04M | $15.87M | $15.87M |
Over the last four quarters, Incannex Healthcare Limited achieved steady financial progress, growing revenue from $0.00 in Q4 2023 to $12000.00 in Q2 2025. Gross profit stayed firm with margins at 100% in Q2 2025 versus N/A in Q4 2023. Operating income totaled -$5.004M in Q2 2025, maintaining a -41700% margin over recent quarters. Despite shifts in R&D and SG&A costs, EBITDA stayed strong at -$5.004M. Net income rose to -$5.89M, with EPS at -$0.33. Disciplined expense strategies and efficient operations ensured sustained profitability and long-term financial stability.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan